{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:30:55Z","timestamp":1775863855363,"version":"3.50.1"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2000,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Oropharyngeal candidiasis (OPC) is a common opportunistic infection in human immunodeficiency virus (HIV)-infected patients and other immunocompromised hosts. Clotrimazole troches are widely used in the treatment of mucosal candidiasis. However, little is known about the potential contribution of clotrimazole resistance to the development of refractory mucosal candidiasis. We therefore investigated the potential emergence of resistance to clotrimazole in a prospectively monitored HIV-infected pediatric population receiving this azole. Adapting the National Committee for Clinical Laboratory Standards M27-A reference method for broth antifungal susceptibility testing of yeasts to clotrimazole, we compared MICs in macrodilution and microdilution assays. We further analyzed the correlation between these in vitro findings and the clinical response to antifungal therapy. One isolate from each of 87 HIV-infected children was studied by the macrodilution and microdilution methods. Two inoculum sizes were tested by the macrodilution method (10\n            <jats:sup>3<\/jats:sup>\n            and 10\n            <jats:sup>4<\/jats:sup>\n            CFU\/ml) in order to assess the effect of inoculum size on clotrimazole MICs. The same isolates also were tested using a noncolorimetric microdilution method. Clotrimazole concentrations ranged from 0.03 to 16 \u03bcg\/ml. Readings were performed after incubation for 24 and 48 h at 35\u00b0C. For 62 (71.2%) of 87 clinical isolates, the MICs were low (\u22640.06 \u03bcg\/ml). The MIC for 90% of the strains tested was 0.5 \u03bcg\/ml, and the highest MIC was 8 \u03bcg\/ml. There was no significant difference between MICs at the two inoculum sizes. There was 89% agreement (\u00b11 tube) between the microdilution method at 24 h and the macrodilution method at 48 h. If the MIC of clotrimazole for an isolate of\n            <jats:italic>C. albicans<\/jats:italic>\n            was \u22650.5 \u03bcg\/ml, there was a significant risk (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001) of cross-resistance to other azoles: fluconazole, \u226564 \u03bcg\/ml (relative risk [RR] = 8.9); itraconazole, \u22651 \u03bcg\/ml (RR = 10). Resistance to clotrimazole was highly associated with clinically overt failure of antifungal azole therapy. Six (40%) of 15 patients for whom the clotrimazole MIC was \u22650.5 \u03bcg\/ml required amphotericin B for refractory mucosal candidiasis versus 4 (5.5%) of 72 for whom the MIC was &lt;0.5 \u03bcg\/ml (\n            <jats:italic>P<\/jats:italic>\n            = 0.001; 95% confidence interval = 2.3 to 22; RR = 7.2). These findings suggest that an interpretive breakpoint of 0.5 \u03bcg\/ml may be useful in defining clotrimazole resistance in\n            <jats:italic>C. albicans<\/jats:italic>\n            . The clinical laboratory's ability to determine MICs of clotrimazole may help to distinguish microbiologic resistance from the other causes of refractory OPC, possibly reducing the usage of systemic antifungal agents. We conclude that resistance to clotrimazole develops in isolates of\n            <jats:italic>C. albicans<\/jats:italic>\n            from HIV-infected children, that cross-resistance to other azoles may develop concomitantly, and that this resistance correlates with refractory mucosal candidiasis.\n          <\/jats:p>","DOI":"10.1128\/jcm.38.4.1563-1568.2000","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T17:55:18Z","timestamp":1577814918000},"page":"1563-1568","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":73,"title":["Emergence of Resistance of\n            <i>Candida albicans<\/i>\n            to Clotrimazole in Human Immunodeficiency Virus-Infected Children: In Vitro and Clinical Correlations"],"prefix":"10.1128","volume":"38","author":[{"given":"Rene\u0301","family":"Pelletier","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Pediatric Oncology Branch1 and"},{"name":"<!--label omitted: 2-->Pavillon l'Ho\u0302tel Dieu de Que\u0301bec, Centre Hospitalier Universitaire de Que\u0301bec, Que\u0301bec, Canada2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Peter","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Pediatric Oncology Branch1 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Antin","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Pediatric Oncology Branch1 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->HIV and AIDS Malignancy Branch,3 National Cancer Institute, Bethesda, Maryland, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Wood","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->HIV and AIDS Malignancy Branch,3 National Cancer Institute, Bethesda, Maryland, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Pediatric Oncology Branch1 and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.1992.11739196"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.31.11.2933-2937.1993"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238182"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/00362177285190521"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/134.4.336"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/132.2.133"},{"key":"e_1_3_2_8_2","first-page":"24","article-title":"Laboratory and clinical studies with clotrimazole","volume":"1","author":"Holt R. J.","year":"1974","unstructured":"Holt R. J. Laboratory and clinical studies with clotrimazole.Postgrad. Med. J.119742426","journal-title":"Postgrad. Med. J."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.25.12.1089"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)90403-8"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00437125"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1977.02120160059009"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(76)81133-X"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(91)90518-H"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.32.4.1115-1118.1994"},{"key":"e_1_3_2_16_2","unstructured":"National Committee for Clinical Laboratory Standards\nReference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M27A.\n1997\nNational Committee for Clinical Laboratory Standards\nVillanova Pa"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(89)90079-5"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199001183220304"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238148"},{"key":"e_1_3_2_20_2","first-page":"271","article-title":"BAY b 5097, a new orally applicable antifungal substance with broad-spectrum activity","volume":"9","author":"Plempel M.","year":"1969","unstructured":"Plempel M. Bartmann K. B\u00fcchel K. H. Regel E. BAY b 5097, a new orally applicable antifungal substance with broad-spectrum activity.Antimicrob. Agents Chemother.91969271274","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.2.235"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.1.1"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198711193172101"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90300-X"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.14.4.517"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.4.2.143-148.1971"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/00362178285380451"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1258"},{"key":"e_1_3_2_29_2","unstructured":"U.S. Pharmacopoeia\nUSP Dl vol. 1: drug information for the health care professional 1995 edition\n1995\n798\nU.S. Pharmacopeia\nRockville Md"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.5.1062"},{"key":"e_1_3_2_31_2","unstructured":"Warren\nN. G.\nHazen\nK. C. Candida Cryptococcus and other yeasts of medical importance\nManual of clinical microbiology\n7th ed.\nMurray\nP. R.\nBaron\nE. J.\nPfaller\nM. A.\nTenover\nF. C.\nYolken\nR. H.\n1999\n1184\n1199\nASM Press\nWashington D.C."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.1997.tb00336.x"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.38.4.1563-1568.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.38.4.1563-1568.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:32:36Z","timestamp":1646440356000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.38.4.1563-1568.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,4]]}},"alternative-id":["10.1128\/JCM.38.4.1563-1568.2000"],"URL":"https:\/\/doi.org\/10.1128\/jcm.38.4.1563-1568.2000","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,4]]},"assertion":[{"value":"1999-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-01-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}